Waxman H L, Myerburg R J, Appel R, Sung R J
Ann Intern Med. 1981 Jan;94(1):1-6. doi: 10.7326/0003-4819-94-1-1.
The effectiveness of verapamil in controlling ventricular rate was evaluated in 20 patients with atrial fibrillation or flutter with a rapid ventricular response (Group 1) and 30 patients with paroxysmal supraventricular tachycardia (Group 2). In Group 1 low-dose verapamil (0.075 mg/kg body weight) decreased the mean ventricular rate from 146 to 114 beats/min (p < 0.01) compared to a decrease of 145 to 132 beats/min (p < 0.01) after placebo. In Group 2, 14 of 29 patients converted to sinus rhythm after low-dose verapamil, nine of 15 after high-dose verapamil (0.15 mg/kg body weight), and one of 24 after placebo (p < 0.01). We conclude that verapamil results in a clinically significant slowing of the ventricular response in atrial fibrillation or atrial flutter and is superior to placebo for conversion of paroxysmal supraventricular tachycardia to sinus rhythm.
对20例伴有快速心室反应的房颤或房扑患者（第1组）和30例阵发性室上性心动过速患者（第2组）评估了维拉帕米控制心室率的有效性。在第1组中，低剂量维拉帕米（0.075mg/kg体重）使平均心室率从146次/分钟降至114次/分钟（p<0.01），而安慰剂组平均心室率从145次/分钟降至132次/分钟（p<0.01）。在第2组中，29例患者中有14例在低剂量维拉帕米治疗后转为窦性心律，15例中有9例在高剂量维拉帕米（0.15mg/kg体重）治疗后转为窦性心律，24例中有1例在安慰剂治疗后转为窦性心律（p<0.01）。我们得出结论，维拉帕米可使房颤或房扑患者的心室反应出现临床上显著的减慢，并且在阵发性室上性心动过速转为窦性心律方面优于安慰剂。
